Migraine Drugs Market Expected to Reach $2,190 Million, Globally, by 2025
The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.
The market was valued at $1,713 million in 2017, and is expected to reach $2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Key Benefits<br />
• North America occupied two-fifths share of the global migraine<br />
drugs market.<br />
• Oral is anticipated <strong>to</strong> grow with the highest CAGR throughout the<br />
forecast period.<br />
• Europe is anticipated <strong>to</strong> occupy more than one-fourth market share<br />
of the global migraine drugs market <strong>by</strong> <strong>2025</strong>.<br />
• Asia-Pacific is anticipated <strong>to</strong> grow at the highest rate during the<br />
analysis period, followed <strong>by</strong> LAMEA.
Change language